Summary

  • A new blood vessel created by North Carolina-based biotechnology company Humacyte has been approved by the US Food and Drug Administration (FDA) for use in patients with traumatic injuries.
  • Made using donated tissue to avoid the risk of rejection,Humacyte’s bioengineered blood vessel is designed to restore blood flow to patients with vascular trauma.
  • Currently, synthetic alternatives made of Teflon or Dacron are used, but these carry a risk of infection as bacteria love to sit on the foreign bodies.
  • The bioengineered vessel was tested in 77 patients, with the results showing it remained open and functioning in almost 92% of patients, compared to 79% for synthetic grafts.
  • Additionally, only 4.5% of patients required amputation, much lower than the 24% when synthetics were used.

Original Article